The biotech industry’s growth prospects look promising due to technological advancements in drug development, the rise in chronic diseases, the growing popularity of personalized medicine, progression in gene therapy, an aging population, and expanding healthcare needs.
Considering this favorable backdrop, investors could look to buy fundamentally strong biotech stocks Biogen Inc. (BIIB) and BioNTech SE (BNTX). However, not all biotech stocks are likely to capitalize on the industry’s growth prospects. Therefore, it could be wise to avoid Kura Oncology, Inc. (KURA), given its poor fundamentals and growth prospects.
